(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available data on polymorphic drug-metabolizing enzyme and tra- porter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience signi?cant bene?ts from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the und- standing of the molecular features of the tumors and the identi?cation of tumor markers of response.
Contents:
pharmacoGENOMICS, ANTICANCER DRUG DISCOVERY, AND RESPONSE Book editor: Federico Innocenti, M.D., Ph.D. Genomic experimental approaches in oncology Toward the realisation of the promise of microarrays in oncology Neil Winegarden Cell based models to identify genetic variants contributing to anticancer drug response M. Eileen Dolan Proteomic analysis in cancer patients Kazuyuki Nakamura MicroRNAs and discovery of new targets Gozoh Tsujimoto Pharmacogenomics of the National Cancer Institute's 60 tumor cell panel David G. Covell Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers Kwong-Kwok Wong Pharmacogenomics of toxicity and response of chemotherapy Concordance between tumor and germline DNA Sharon Marsh Epidermal growth factor receptor mutations and sensitivity to selective kinase inhibitors in human lung cancer Jeffrey Settleman 3. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients Mark Litzow Role of thymidylate synthase gene variations in colorectal cancer patients Heinz-Josef Lenz Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-methyltransferase gene Martin Stanulla The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies Dong Hwan Kim DNA repair and mitotic check point genes as potential predictors of chemotherapy response in non-small-cell lung cancer Rafael Rosell Dihydropyrimidine dehydrogenase (DPYD) gene polymorphism: portrait of a serial killer. Gerard Milano Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment Kimie Sai Microarray profiling in breast cancer patients Lan Guo 11. Role of the folate pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response Richard Aplenc Pharmacogenomics in clinical drug development in oncology Pharmacogenomics in drug development: an pharmaceutical industry perspective Tal Zaks Identification of a pharmacogenomic biomarker classifiers in cancer drug development Richard Simon Toxicogenomics application to oncology drug development Teresa Lettieri Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches Xifeng Wu
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 392
Weight: 972g
Availability: Available
Subcategories: Genetics, Oncology, Pharmacology
Publisher recommends
Federico Innocenti
From the same series
Nicola Curtin
Jorge J. Castillo
Moulay A. Alaoui-Jamali
Gail Lewis Phillips
Frank E. Koehn
Beverly A. Teicher
Gary J. Kelloff
Ryan J. Sullivan
Gary K Schwartz
Val R Adams
Antonio Tito Fojo
William D. Figg
Steven Kanner
Giovanni Melillo
Masaki Terabe
Yves Pommier
Derek LeRoith
Beverly A. Teicher
Ann L. Jackman
Jorge J. Castillo
Manuel Hidalgo
Vinata B. Lokeshwar
Beverly A. Teicher
Moulay A. Alaoui-Jamali
Saïd M. Sebti
Frank E. Koehn
Rebecca G. Bagley
Vitaly A. Polunovsky
Benjamin Bonavida
Beverly A. Teicher
Alan M. Gewirtz
Michael A Morse
Janusz W. Rak
J. Silvio Gutkind
Maryann Foote
Zahid H. Siddik
L. Harivardhan Reddy
Gavin J. Gordon
Masaki Terabe
Yves Pommier
Derek LeRoith
Neil J. Clendeninn
Howard L. Kaufman
John D. Haley
Manuel Hidalgo
Beverly A. Teicher
Ulrike Stein
Pat Price
Kelly K. Hunt
Mary L. Disis
David A. Gewirtz
Beverly A. Teicher
Sayed S. Daoud
Nicholas P. Farrell
Vinata B. Lokeshwar
Beverly A. Teicher
Giampietro Gasparini
Doriano Fabbro
Nicholas B. La Thangue
David E. Fisher
Beverly A. Teicher
John A. Hickman
Godefridus J. Peters
Julian Adams
Sonia Jakowlew
Antonio Giordano
Youcef M. Rustum
Michel Page
Gurmit Singh
Gary J. Kelloff
Moulay A. Alaoui-Jamali
Wafik S. El-Deiry
Keiko Hiyama
Amy M. Fulton
Hak Choy
Sonia Jakowlew
Dennis M. Brown
Michael T. Lotze
Randall E. Harris
Eric Verdin
Benjamin Bonavida
Rebecca G. Bagley
Vitaly A. Polunovsky
Benjamin Bonavida
L. Harivardhan Reddy
V. Craig Jordan
Zahid H. Siddik
Erwin G. van Meir
Amy M. Fulton
Beverly A. Teicher
Keiko Hiyama
Gavin J. Gordon
David S. Ettinger
Federico Innocenti
John D. Haley
Benjamin Bonavida
Antonio Tito Fojo
Sonia Jakowlew
Sonia Jakowlew
Howard L. Kaufman
David A. Gewirtz
Beverly A. Teicher
Sayed S. Daoud
Pat Price
Michael T. Lotze
Ulrike Stein
Kelly K. Hunt
Godefridus J. Peters
Beverly A. Teicher
Eric Verdin